The coronary stents industry is a highly competitive one in which innovation occurs rapidly and the technology landscape evolves at a fast pace. As the global population is aging and has a longer life expectancy, the prevalence of coronary heart disease and co-morbid conditions such as hypertension, diabetes and obesity is projected to rise and stimulate the demand for coronary stents. Additionally, a growing acceptance of drug-eluting stents as a more effective treatment for coronary heart disease, along with increasing awareness about coronary stents among patients, is expected to boost procedural volumes. New technologies, such as bioresorbable scaffolds, and bifurcation and biodegradable polymers stents, are projected to enter major markets in the next years and increase the utilization of stents in interventional cardiology.
Despite the challenging environment, opportunities still exist in the global market for coronary stents, as there is still a high need for non-invasive therapies with enhanced safety and efficacy, and there are various niches of the market, such as bifurcation and complex lesions, that require more extensive treatment options. Additionally, the new bioresorbable stents have the potential to eliminate the negative issues of durable polymer stents, and are therefore expected to induce a significant shift in the treatment of coronary heart disease, encouraging also more patients to undergo stent implantation surgery.
This Report, The World Market for Stents (Drug Eluting and Bare Metal Product Markets in U.S., E.U., Japan, China, India and ROW), authored by medical device analyst Adriana Rusu, provides a complete overview of cardiovascular disease, the role of stents in treatment, the success of bare metal and drug-eluting products, as well as market sizes and forecasts to 2017. Included in this reports coverage:
Market Size and Forecast -Cardiovascular Disease Statistics (Mortality, Morbidity, Cost by Country)
Regional Breakout of Bare Metal and Drug-Eluting Stent Markets (U.S., E.U., Japan, China, India, ROW)
Categorization of Drug-Eluting Stents by Polymer, Drug, Platform
Coronary Stents Using Biodegradable Polymers, Novel Coating and Direct Drug Application
Assessment of Bioresorbable Stents
Dedicated Bifurcation, Dedicated Small Vessel Stent Products
Major Competitors Market Share
Significant Trends in Market and Near and Long-Term Impact
Recent Mergers and Acquisitions
Key Company Profiles
The major markets of US, Europe, and Japan experienced significant challenges in recent years, including price declines, decreasing volumes of percutaneous coronary interventions, and lower penetration rates for drug-eluting stents resulted from cost constraints and reductions in healthcare budgets. Additionally, the intensified competition among manufacturers also contributed to the decline in average stent selling prices in these regions. Despite that, the market potential for coronary stents in these regions remains quite attractive, given the aging population and high longevity. However, the decreasing reimbursement rates and the intensifying competition for market share are expected to continue to lead to price declines and hamper significantly the market growth.
As part of its coverage of the stents industry, the following companies are profiled:
Biotronik SE & Co.KG
Elixir Medical Corporation
Meril Life Sciences Pvt. Ltd.
MicroPort Medical (Shanghai) Co., Ltd Minvasys
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives.